Last reviewed · How we verify
Placebo - LNG
Placebo - LNG is a Small molecule drug developed by The University of Hong Kong. It is currently in Phase 3 development for Control arm in Phase 3 trial (specific indication unknown).
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in Phase 3 trial (specific indication unknown).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo - LNG |
|---|---|
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Therapeutic area | Contraception or Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
Placebo-LNG refers to an inert control formulation used in a Phase 3 trial, likely comparing against a levonorgestrel (LNG)-based contraceptive or hormonal therapy. The placebo arm provides no pharmacological effect and serves as the comparator to establish efficacy of the active treatment.
Approved indications
- Control arm in Phase 3 trial (specific indication unknown)
Common side effects
Key clinical trials
- Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel (PHASE3)
- Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia (PHASE2)
- Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men (PHASE2)
- Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo (PHASE4)
- IUD and Norethindrone Acetate for Treatment of Endometriosis (PHASE2)
- Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception (PHASE3)
- Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel (PHASE4)
- Effect of Propolis Administration for Dysmenorrhea in Endometriosis Patient With Levonorgestrel Implant Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo - LNG CI brief — competitive landscape report
- Placebo - LNG updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI
Frequently asked questions about Placebo - LNG
What is Placebo - LNG?
How does Placebo - LNG work?
What is Placebo - LNG used for?
Who makes Placebo - LNG?
What development phase is Placebo - LNG in?
Related
- Manufacturer: The University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Contraception or Reproductive Health
- Indication: Drugs for Control arm in Phase 3 trial (specific indication unknown)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing